Pacira ((PCRX)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pacira Pharmaceuticals is conducting a Phase 2 clinical study titled ‘A Phase 2, Two-Part, Randomized, Double-Blind, Active-Controlled Study to Assess the Safety and Tolerability of Enekinragene Inzadenovec (PCRX-201) in Subjects With Painful Osteoarthritis of the Knee.’ The study aims to evaluate the safety and tolerability of PCRX-201, a potential treatment for knee osteoarthritis, in patients aged 45 to 80. This research is significant as it explores a new therapeutic option for managing osteoarthritis pain.
The intervention being tested is Enekinragene Inzadenovec (PCRX-201), a biological treatment administered via a single intra-articular injection. The study compares two doses of PCRX-201 against a placebo to determine its safety and efficacy.
The study design is interventional, with participants randomly assigned to different groups receiving either Dose A, Dose B, or a placebo. It employs a parallel intervention model and uses quadruple masking to ensure unbiased results. The primary purpose of the study is treatment-focused.
The study began on March 13, 2025, with the latest update submitted on June 21, 2025. These dates are crucial as they mark the study’s progress and ongoing recruitment status.
This study could significantly impact Pacira’s stock performance by potentially introducing a new product to the market, enhancing investor sentiment. The development of PCRX-201 could position Pacira competitively within the osteoarthritis treatment market, influencing industry dynamics.
The study is currently recruiting, with further details available on the ClinicalTrials portal.